Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 7-10 Year Treasury Bond ETF vs Merck & Co., Inc. — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $93.1, while Merck & Co., Inc. trades at $131.63 (market cap $321.77B). The key difference: Merck & Co., Inc. pays a 2.61% dividend while iShares 7-10 Year Treasury Bond ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| IEF | MRK | |
|---|---|---|
52-Week High | $97.99 | $131.84 |
52-Week Low | $92.76 | $77.60 |
Market Cap | — | $321.77B |
Sector | — | Health |
Enterprise Value | — | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEF, an ETF tracking 7-10 year US Treasury bonds, trades at $93.13, up 0.4% on the day. Technical indicators are bearish overall, with moving averages signaling sell pressure, while oscillators are neutral. Recent news highlights institutional buying interest amid rising Treasury yields and inflation concerns. The ETF pays regular dividends, with recent distributions around $0.31-$0.32 per share.
The outlook for IEF hinges on interest rate trends and inflation data. Higher yields may pressure prices, but institutional accumulation suggests long-term confidence. Key risks include Fed policy shifts and geopolitical tensions affecting oil prices and bond markets. Investors should weigh yield attractiveness against duration risk in a volatile rate environment.
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
